Patents by Inventor Chixu Chen

Chixu Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER
    Publication number: 20250326772
    Abstract: The present disclosure relates to compounds represented by structural formula (I*): or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical compositions comprising the compounds and methods of treating an MRGPRX2-mediated disease or disorder using the compounds.
    Type: Application
    Filed: April 18, 2025
    Publication date: October 23, 2025
    Inventors: Mariangela Urbano, Eun-Kyong Kim, Chixu Chen, Damoder R. Motati, Romelo Gibe, Shyama Herath, Qiang Li, Naresh Gunaganti, Xiuwen Zhu, Mohammad B. Khaled, Jonathan S. Rosenblum, Hugh Rosen, Sean Riley, Emme C.K. Lin Fishburn, Ryosuke Namie, Akihiko Kojima, Yoshikazu Asahina, Yosuke Nishigaya, Muneki Nagao, Akihiko Kasamatsu, Takekazu Kondo
  • MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER
    Publication number: 20250326773
    Abstract: The present disclosure relates to compounds represented by structural formula (I*): or a pharmaceutically acceptable salt thereof. Further disclosed are pharmaceutical compositions comprising the compounds and methods of treating an MRGPRX2-mediated disease or disorder using the compounds.
    Type: Application
    Filed: June 25, 2025
    Publication date: October 23, 2025
    Inventors: Mariangela Urbano, Eun-Kyong Kim, Chixu Chen, Damoder R. Motati, Romelo Gibe, Shyama Herath, Qiang Li, Naresh Gunaganti, Xiuwen Zhu, Mohammad B. Khaled, Jonathan S. Rosenblum, Hugh Rosen, Sean Riley, Emme C.K. Lin Fishburn, Ryosuke Namie, Akihiko Kojima, Yoshikazu Asahina, Yosuke Nishigaya, Muneki Nagao, Akihiko Kasamatsu, Takekazu Kondo
  • 15-PGDH INHIBITORS
    Publication number: 20220073494
    Abstract: A compound having one of formula (1), formula (2), formula (3) and formula (4) or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: January 29, 2020
    Publication date: March 10, 2022
    Inventors: Shyama HERATH, Mariangela URBANO, Eun-Kyong KIM, Chixu CHEN, Qiang LI, Julia AYERS, Kaikoo NAKAMURA, Xiuwen ZHU, Hugh ROSEN, Jonathan S. ROSENBLUM, Melissa C. ZHANG, Yongsheng LIU, Masahiro UENO
  • THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20210171466
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Application
    Filed: December 16, 2020
    Publication date: June 10, 2021
    Inventors: Samedy OUK, Esmir GUNIC, Jean-Michel VERNIER, Chixu CHEN
  • Thioacetate compounds, compositions and methods of use
    Patent number: 10919858
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: February 16, 2021
    Assignee: Ardea Biosciences, Inc
    Inventors: Samedy Ouk, Esmir Gunic, Jean-Michel Vernier, Chixu Chen
  • THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20190185431
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Application
    Filed: November 14, 2018
    Publication date: June 20, 2019
    Inventors: Samedy Ouk, Esmir Gunic, Jean-Michel Vernier, Chixu Chen
  • Thioacetate compounds, compositions and methods of use
    Patent number: 10266493
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: April 23, 2019
    Assignee: Ardea Biosciences, Inc.
    Inventors: Samedy Ouk, Esmir Gunic, Jean-Michel Vernier, Chixu Chen
  • THIOACETATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
    Publication number: 20130202573
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Application
    Filed: June 15, 2011
    Publication date: August 8, 2013
    Applicant: Ardea Biosciences, Inc.
    Inventors: Samedy Ouk, Esmir Gunic, Jean-Michel Vernier, Chixu Chen
  • Fused ring heterocycle kinase modulators
    Patent number: 8268994
    Abstract: The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: September 18, 2012
    Assignee: SGX Pharmaceuticals, Inc.
    Inventors: William D. Arnold, Pierre Bounaud, Chixu Chen, Brian Eastman, Andreas Gosberg, Stefan N. Gradl, Stephanie Hopkins, Zhe Li, Ian McDonald, Paul A. Sprengeler, Ruo W. Steensma, Mark E. Wilson
  • Fused ring heterocycle kinase modulators
    Patent number: 8242280
    Abstract: The present invention provides fused ring heterocycles as kinase modulators, pharmaceutical compositions containing these modulators, and methods of using these modulators to treat diseases mediated by kinase activity.
    Type: Grant
    Filed: April 10, 2008
    Date of Patent: August 14, 2012
    Assignee: SGX Pharmaceuticals, Inc.
    Inventors: Chixu Chen, Brian Eastman, Andreas Gosberg, Stefan N. Gradl, Gavin Hirst, Stephanie Hopkins, Khanh Thi Tuong Nguyen, Richard Pracitto, Paul E. Sprengeler, Ruo W. Steensma
  • Pyrimidinyl-thiophene kinase modulators
    Patent number: 7977481
    Abstract: The present invention provides novel pyrimidinyl-thiophene kinase modulators and methods of using the novel pyrimidinyl-thiophene kinase modulators to treat diseases mediated by kinase activity.
    Type: Grant
    Filed: August 6, 2010
    Date of Patent: July 12, 2011
    Assignee: SGX Pharmaceuticals, Inc.
    Inventors: William D. Arnold, Chixu Chen, Stefan N. Gradl, Stephanie Hopkins, Ruo W. Steensma, Masaki Tomimoto, Mark E. Wilson
  • Pyrimidinyl-Thiophene Kinase Modulators
    Publication number: 20100305128
    Abstract: The present invention provides novel pyrimidinyl-thiophene kinase modulators and methods of using the novel pyrimidinyl-thiophene kinase modulators to treat diseases mediated by kinase activity.
    Type: Application
    Filed: August 6, 2010
    Publication date: December 2, 2010
    Inventors: William D. Arnold, Chixu Chen, Stefan N. Gradl, Stephanie A. Hopkins, Ruo W. Steensma, Masaki Tomimoto, Mark E. Wilson
  • Pyrimidinyl-thiophene kinase modulators
    Patent number: 7803806
    Abstract: The present invention provides novel pyrimidinyl-thiophene kinase modulators and methods of using the novel pyrimidinyl-thiophene kinase modulators to treat diseases mediated by kinase activity.
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: September 28, 2010
    Assignee: SGX Pharmaceuticals, Inc.
    Inventors: William D. Arnold, Chixu Chen, Stefan N. Gradl, Stephanie A. Hopkins, Ruo W. Steensma, Masaki Tomimoto, Mark E. Wilson
  • Inhibitors of Akt activity
    Patent number: 7750151
    Abstract: The present invention is directed to compounds which contain substituted napthyridines which inhibit the activity of Akt, a serine/threonine protein kinase. The invention is further directed to chemotherapeutic compositions containing the compounds of this invention and methods for treating cancer comprising administration of the compounds of the invention.
    Type: Grant
    Filed: April 5, 2005
    Date of Patent: July 6, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mark T. Bilodeau, Chixu Chen, Nicholas D. P. Cosford, Brian W. Eastman, John C. Hartnett, Essa H. Hu, Peter J. Manley, Lou Anne Neilson, Lida R. Tehrani, Zhicai Wu
  • Pyrrolo-pyridine kinase modulators
    Patent number: 7709645
    Abstract: The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: May 4, 2010
    Assignee: SGX Pharmaceuticals, Inc.
    Inventors: William D Arnold, Pierre Bounaud, Chixu Chen, Brian Eastman, Andreas Gosberg, Stefan N. Gradl, Stephanie Hopkins, Zhe Li, Ian McDonald, Paul A. Sprengeler, Ruo W. Steensma, Mark E. Wilson
  • Inhibitors of AKT activity
    Patent number: 7705014
    Abstract: The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of treatment of cancer.
    Type: Grant
    Filed: April 10, 2006
    Date of Patent: April 27, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Chixu Chen, Brian W. Eastman, Essa H. Hu
  • Fused Ring Heterocycle Kinase Modulators
    Publication number: 20100036118
    Abstract: The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.
    Type: Application
    Filed: August 11, 2009
    Publication date: February 11, 2010
    Inventors: William D. Arnold, Pierre Bounaud, Chixu Chen, Brian Eastman, Andreas Gosberg, Stefan N. Gradl, Stephanie Hopkins, Zhe Li, Ian McDonald, Paul A. Sprengeler, Ruo W. Steensma, Mark E. Wilson
  • Fused ring heterocycle kinase modulators
    Patent number: 7626021
    Abstract: The present invention provides novel fused ring heterocycle kinase modulators and methods of using the novel fused ring heterocycle kinase modulators to treat diseases mediated by kinase activity.
    Type: Grant
    Filed: April 10, 2007
    Date of Patent: December 1, 2009
    Assignee: SGX Pharmaceuticals, Inc.
    Inventors: William D. Arnold, Pierre Bounaud, Chixu Chen, Brian Eastman, Andreas Gosberg, Stefan N. Gradl, Stephanie Hopkins, Zhe Li, Ian McDonald, Paul A. Sprengeler, Ruo W. Steensma, Mark E. Wilson
  • Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
    Patent number: 7592337
    Abstract: Tetrazole compounds substituted directly, or by a bridge, with i) a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl and ii) another heteroaryl or aryl ring, with at least one of the rings being further substituted with another ring, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, drug addiction, drug abuse, drug withdrawal, obesity and other diseases.
    Type: Grant
    Filed: March 7, 2003
    Date of Patent: September 22, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Chixu Chen, Nicholas D. P. Cosford, Brian W. Eastman, Dehua Huang, Steve F. Poon, Thomas S. Reger, Jeffrey R. Roppe, Nicholas D. Smith
  • Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
    Patent number: 7569592
    Abstract: Pyrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.
    Type: Grant
    Filed: December 13, 2002
    Date of Patent: August 4, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Nicholas D. P. Cosford, Chixu Chen, Brian W. Eastman, Dehua Huang, Benito Munoz, Petpiboon Prasit, Nicholas D. Smith